<DOC>
	<DOCNO>NCT01525641</DOCNO>
	<brief_summary>Post-marketing surveillance ( PMS ) investigate safety efficacy long-term daily use Mirapex®-LA Tablets patient Parkinson 's disease .</brief_summary>
	<brief_title>Safety Efficacy Long-term Daily Use Mirapex®-LA Tablets Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : Patients Parkinson 's disease never treat Mirapex LA Tablets enrolment include . Exclusion criterion : None</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>